Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.58 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.58 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613112 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12314757 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL18215662 | 0.95 | SCN9A (0.90) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2579654 | 0.92 | SCN9A (0.85) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329179 | 0.91 | SCN9A (0.84) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2586519 | 0.90 | SCN9A (0.82) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3336216 | 0.90 | SCN9A (0.81) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2303907 | 0.90 | SCN9A (0.81) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2308037 | 0.89 | SCN9A (0.80) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329687 | 0.89 | SCN9A (0.80) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-20160326184-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-11-10 | — | — | US | disclosed |
| US-20160326184-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2016-11-10 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9260446-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2016-02-16 | — | — | US | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| EP-2488531-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | Xenon Pharmaceuticals Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011047174-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047174-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-21 | — | — | WO | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | TRPV1, TRPV5, TRPV3 | SCN9A 47/4885SCN7A 44/4885SCN5A 15/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
| US-20160326184-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | TRPV1, TRPV5, TRPV3 | SCN9A 47/4885SCN7A 44/4885SCN5A 15/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | SCN9A 61/4885SCN7A 72/4885SCN5A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.